Response to “Bupivacaine Liposomal versus Bupivacaine: Comparative Review”

Schmidt W.K. Patou G. Joshi Girish P. Evaluating therapeutic benefit in postsurgical analgesia requires global assessment: An example from liposome bupivacaine in hemorrhoidectomy. Hosp Pract. 2012; 40: 160–165.

Cohen S.M.x An extended pain relief trial utilizing infiltration of Exparel, a long-acting multivesicular liposome formulation of bupivacaine: A phase IV health economic trial in adult patients undergoing open colectomy. J Pain Res. 2012; 5: 567–572.

Marcet J. Nfonsam V. Larach S. An extended pain relief trial utilizing the infiltration of a long-acting multivesicular liposome formulation of bupivacaine, Exparel (IMPROVE): A phase IV health economic trial in adult patients undergoing ileostomy reversal. J Pain Res. 2013; 6: 549–555.

Candiotti K. Sands L.R. Lee E. Liposomal bupivacaine for postsurgical analgesia in adult patients undergoing laparoscopic colectomy: Results from prospective phase IV sequential cohort studies assessing health economic outcomes. Curr Ther Res. 2014; 76: 1–6.

Cohen S.M. Vogel J.D. Marcet J.E. Candiotti K.A. Liposomal bupivacaine for improvement in economic outcomes and opioid burden in GI surgery: IMPROVE study pooled analysis. J Pain Res. 2014; 7: 359–366.

Barrington J.W. Emerson R. Liposomal bupivicaine: The first 1,000 cases in a new era. Abstract presentation at the American Academy of Orthopaedic Surgeons; March 2014.

Kessler E.R. Shah M. Gruschkus S.K. Raju A. Cost and quality implications of opioid-based postsurgical pain control using administrative claims data from a large health system: Opioid-related adverse events and their impact on clinical and economic outcomes. Pharmacotherapy. 2013; 33(4): 383–391.

American Society of Health-System Pharmacists (ASHP) and the Society of Hospital Medicine (SHM) joint survey examines hospital formulary decisions [Press release, June 10, 2010].

Bramlett K. Onel E. Viscusi E.R. Jones K. A randomized, double-blind, dose-ranging study comparing wound infiltration of DepoFoam bupivacaine, an extended-release liposomal bupivacaine, to bupivacaine HCl for postsurgical analgesia in total knee arthroplasty. Knee. 2012; 19: 530–536.

Exparel [package insert]. San Diego, CA: Pacira Pharmaceutics, Inc; June 2012.

Cohen S.M. An extended pain relief trial utilizing infiltration of Exparel, a longacting multivesicular liposome formulation of bupivacaine: A phase IV health economic trial in adult patients undergoing open colectomy. J Pain Res. 2012; 5: 567–572.

Bagsby D.T. Ireland P.H. Meneghini R.M. Liposomal bupivacaine versus traditional periarticular injection for pain control after total knee arthroplasty [published online ahead of print April 4, 2014]. J Arthroplasty. doi: 10.1016/j.arth.2014.03.034.